Cardiology PoC Diagnostics Market Size, Share & Trends Analysis Report By Product (Cholesterol/Lipid Profile Test, Cardiac Bio/Markers, Coagulation Test, Companion Diagnostics), By Technology (Lateral Flow Test (LFT), Optical Liquid Analysis, Electrical Biochemical Sensors, Molecular Diagnostics), By End User (Hospitals, Diagnostic Laboratories, Home-based Testing, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Cardiology PoC Diagnostics Market Size & Growth Analysis

The global cardiology poc diagnostics market size was valued at USD 2.05 billion in 2025 and is projected to grow from USD 2.17 billion in 2026 to USD 3.37 billion by 2034, registering a CAGR of 5.68% during the forecast period from 2026 to 2034. North America dominated the cardiology poc diagnostics market with a market share of 35.47% in 2025.

The cardiology point-of-care (PoC) diagnostics market refers to the segment of healthcare diagnostics focused on rapid, near-patient testing for cardiovascular conditions to enable timely clinical decisions. It encompasses products such as cholesterol/lipid profile tests, cardiac biomarkers, coagulation tests, and companion diagnostics designed to detect, monitor, and manage cardiac disorders. The market is characterized by the adoption of diverse technologies, including lateral flow tests (LFT), optical liquid analysis, electrical biochemical sensors, and molecular diagnostics, which enhance accuracy and turnaround time of cardiac testing. These diagnostic solutions are utilized across various end users such as hospitals, diagnostic laboratories, home-based testing setups, and other healthcare facilities, aiming to improve cardiac care delivery through faster and more accessible diagnostic results.

Product Insights

The cholesterol/lipid profile test segment dominated the market in 2025, accounting for 39.42% of total revenue. This dominance was driven by the widespread use of lipid screening in cardiovascular risk assessment and routine health check-ups. The availability of compact PoC lipid analyzers in hospitals and clinics enhanced testing convenience, reducing dependence on centralized laboratories. Growing awareness of early cholesterol management among adults further supported high utilization across diagnostic facilities and primary care settings.

The cardiac biomarkers segment is projected to register the fastest growth, at a CAGR of 6.12% during the forecast period. Increasing adoption of high-sensitivity cardiac troponin and BNP tests for early myocardial infarction detection is fueling expansion. Rising preference for rapid PoC assays in emergency and acute care settings is accelerating this trend. Continuous advancements in immunoassay technology and miniaturised testing devices are making cardiac biomarker testing more accessible across hospital networks and ambulatory care units.

Request Customizationto receive a tailored report.

Technology Insights

The lateral flow test (LFT) segment led the market in 2025, representing 47.25% of total revenue. This growth was supported by the widespread availability of LFT-based PoC assays for rapid cardiac biomarker testing in both hospitals and field settings. The segment’s popularity stems from its simple operation, affordability, and short turnaround time, which make it suitable for primary healthcare and emergency use. Adoption of LFTs in developing economies has expanded rapidly due to the convenience of deploying test kits without complex laboratory infrastructure.

The molecular diagnostics segment is expected to grow at the fastest rate, recording a CAGR of 6.35% during the forecast period. The increasing use of molecular testing technologies for identifying genetic and biochemical cardiac risk factors is driving this trend. Demand for high-precision and portable PCR-based PoC devices is rising among hospitals and specialty clinics focusing on advanced cardiovascular diagnostics. Continuous development of multiplex molecular platforms that deliver rapid results supports their integration into both clinical and decentralized care environments.

End User Insights

The diagnostic laboratories segment dominated the market in 2025 with a 42.34% share. High testing throughput, established infrastructure, and wide availability of qualified personnel supported the segment’s leadership. Diagnostic labs continue to serve as the primary centers for comprehensive cardiac biomarker testing and result validation. The integration of PoC analyzers within laboratory workflows improved testing efficiency, reducing result turnaround time for cardiac assessments across healthcare facilities.

The home-based testing segment is projected to record the fastest growth, at a CAGR of 6.78% during the forecast period. The shift toward decentralized diagnostics and the availability of portable PoC analyzers for cholesterol and cardiac marker testing have supported adoption in residential settings. Rising public awareness of preventive cardiac care and the growing popularity of self-testing kits have expanded the patient base for home-use PoC devices. The increasing connectivity of PoC analyzers with mobile health platforms is further supporting early detection and remote cardiac monitoring.

Speak to an Analystto discuss market opportunities.

Regional Analysis

North America dominated the cardiology point-of-care diagnostics market with the largest revenue share of around 35.47% in 2025. The region’s growth was driven by the integration of rapid cardiac biomarker testing within emergency departments, outpatient clinics, and diagnostic laboratories. Supportive reimbursement frameworks for PoC cardiac assays encouraged hospitals to adopt portable testing platforms, improving clinical workflows for cardiac patients. Collaborations between device manufacturers and hospital networks enabled wider deployment of PoC troponin and BNP analyzers across acute care settings.

The U.S. market expanded with the increased adoption of high-sensitivity troponin PoC assays for early myocardial infarction detection. Hospitals accelerated their transition from centralized laboratory testing to bedside PoC platforms to reduce turnaround time in emergency care. The growing use of portable analyzers in cardiac rehabilitation centers enhanced continuity of care, while partnerships between hospitals and diagnostic companies promoted standardized protocols for cardiac biomarker testing.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Market Insights

Asia Pacific is anticipated to register the fastest CAGR of 7.68% during the forecast period, fueled by increasing cardiovascular disease prevalence, urbanization, and healthcare infrastructure expansion. Rising government focus on decentralized diagnostics encouraged adoption of PoC cardiac testing in primary and secondary care centers. Investments in local manufacturing and distribution enhanced access to affordable cardiac biomarker analyzers across developing economies.

China’s market advanced with strong policy initiatives promoting early cardiac disease detection through PoC diagnostic systems. Hospitals incorporated portable analyzers for cardiac troponin and lipid testing in outpatient settings to shorten diagnostic delays. Domestic firms developed compact analyzers suited for community health centers, supporting broader implementation of cardiac screening and preventive programs under national healthcare reforms.

Europe Market Insights

Europe holds a notable share of the cardiology PoC diagnostics market in 2025, driven by established cardiac care networks emphasizing rapid diagnostic triage. The region’s healthcare systems supported PoC testing integration into emergency and ambulatory services to accelerate treatment initiation for acute coronary syndromes. Widespread availability of PoC analyzers across national health systems strengthened clinical readiness for cardiac emergencies.

Germany’s market grows through the expansion of hospital-based PoC programs that prioritize bedside cardiac biomarker testing. Health institutions introduced troponin and D-dimer PoC analyzers within emergency departments to improve patient throughput and diagnostic accuracy. Continuous collaboration between medical device manufacturers and public health authorities supported deployment of standardized PoC platforms aligned with national cardiac care guidelines.

Middle East & Africa Market Insights

The Middle East and Africa demonstrated steady market expansion as countries strengthened cardiac care infrastructure. Governments initiated national screening campaigns and supported PoC diagnostic integration within tertiary and specialty hospitals. The growing number of diagnostic laboratories adopting cardiac biomarker testing platforms contributed to increased utilization of PoC systems across the region.

Saudi Arabia’s market progressed through large-scale healthcare transformation efforts aligned with Vision 2030. Hospitals incorporated PoC cardiac assays for monitoring acute coronary syndromes and post-rehabilitation follow-ups. Strategic alliances between local healthcare providers and global diagnostics companies improved access to PoC testing technology, supporting faster cardiac risk evaluation and patient management.

Latin America Market Insights

Latin America experienced market growth in 2025, supported by national cardiovascular health initiatives and modernization of diagnostic infrastructure. Expansion of public screening programs for heart disease and partnerships with diagnostic manufacturers improved the adoption of PoC analyzers across hospitals and clinics. The shift toward decentralized diagnostics increased accessibility in both urban and rural healthcare facilities.

Brazil’s market expanded as public health agencies introduced cardiac PoC testing programs within primary healthcare centers. Integration of PoC troponin and lipid testing devices into government-led screening projects under the Unified Health System (SUS) improved early diagnosis of cardiovascular conditions. Domestic collaborations with diagnostic companies enhanced device affordability, ensuring broader reach among lower-income populations.

Competitive Landscape

The global cardiology point-of-care (PoC) diagnostics market is moderately fragmented, comprising leading diagnostics giants, specialized cardiac assay developers, and emerging innovators focused on rapid testing, molecular diagnostics, and AI-integrated solutions.

Abbott: An emerging market player

Abbott maintains a strong position in the cardiology PoC diagnostics market with its broad product portfolio, including i-STAT and Alinity platforms, offering rapid cardiac biomarker testing such as troponin, BNP, and D-dimer. The company continues to expand its high-sensitivity cardiac troponin (hs-cTn) assays to emergency and critical care settings.

• In March 2024, Abbott launched an upgraded i-STAT TnI-Next cartridge designed for faster turnaround and enhanced analytical accuracy, strengthening its foothold in hospital and emergency PoC testing.

List of Key and Emerging Players in Cardiology PoC Diagnostics Market